Latest Conference Coverage

Accounting for Practice Effects on the MS Performance Test

Stephen Rao, PhD, ABPP-Cn, the Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic, discussed the development of the MSPT.

Assessing Atrophied Lesion Volume in Progressive MS: Robert Zivadinov, MD, PhD

The professor of neurology and director of the Buffalo Neuroimaging Analysis Center discussed the background of the ORATORIO study and the aT2-LV biomarker.

Characterizing Generalized Epilepsy in Elders: Vineet Punia, MD, MS

The neurologist at Cleveland Clinic discussed how his data may change clinicians’ perception on the management and prevalence of generalized epilepsy in elders.

Investigating Disparities in Post-Stroke Rehabilitation

Sana Somani, MD, MBBS, vascular neurology fellow at the University of Maryland Medical Center, discussed her research into disparities in post-stroke care.

Imaging Demonstrates Ocrelizumab’s Impact in Progressive MS: Robert Zivadinov, MD, PhD

The professor of neurology and director of the Buffalo Neuroimaging Analysis Center discussed his work on the ORATORIO study.

Patients With Chronic Migraine More Likely to Face Barriers to Successful Migraine Care

Monitoring Progression in Multiple Sclerosis: Stephen Rao, PhD, ABPP-Cn

The Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic discussed his investigations into improving the MSPT.

Improving Post-Stroke Outcomes With Personalized Discharge Instructions

Marian LaMonte, MD, MSN, FAAN, chief of neurology at Ascension Saint Agnes, discussed her team’s efforts to improve compliance in providing stroke discharge instructions.

Correcting Practice Effects on the MSPT: Stephen Rao, PhD, ABPP-Cn

The Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic discussed the importance of correcting practice effects to determine performance.

Expanding Accessibility of MANAGE-PD Screening Tool: Hubert Fernandez, MD

The director of the Center for Neurological Restoration at Cleveland Clinic discussed future ideas for the MANAGE-PD tool to furthering its benefits.

Reevaluating Prevalence and Management of Generalized Epilepsy in Elders

Vineet Punia, MD, MS, shared thoughts on his study from AAN 2021 which characterized generalized epilepsy in older adults and the elderly, and raised questions about its overall prevalence.

Assessing Accuracy in Teleneurology for Stroke Consultations

Jason Poon, MD, neurologist at University of Utah, discussed his study on diagnostic accuracy in telestroke consultations.

Atrophied Lesion Volume as Biomarker in Progressive MS: Robert Zivadinov, MD, PhD

The professor of neurology and director of the Buffalo Neuroimaging Analysis Center discussed the development of the aT2-LV biomarker.

NeuroVoices: Stephanie J. Nahas, MD, on Migraine Treatment Gaps and Optimization

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed treatment optimization for patients with migraine and raising overall awareness for preventive treatments.

Mass Screening for Cognitive Changes: Richard Gershon, PhD

The vice chair for research at the Northwestern University Feinberg School of Medicine discussed the potential of the mobile toolbox battery to screen hundreds of thousands for cognitive impairment.

Exploring New Ways of Using Responsive Neurostimulation in Epilepsy: Vineet Punia, MD, MS

The neurologist from Cleveland Clinic offered his insight into the areas that he believes responsive neurostimulation could provide benefit to patients that need further examination.

Investigating IMU-838 for Relapsing MS

Robert Fox, MD, Vice-Chair for Research at the Cleveland Clinic Neurological Institute, discussed the findings of the phase 2 EMPhASIS trial of this investigational MS therapy.

Advantages of Sublingual Apomorphine in Parkinson Disease: Jennifer S. Hui, MD

The assistant professor of neurology at the Keck School of Medicine at University of Southern California shared her insight into the study data and the therapy’s potential advantages for patients with Parkinson disease.

Factors That Influence Practice Effects: Stephen Rao, PhD, ABPP-Cn

The Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic discussed populations that exhibit greater practice effects than others.

Improving Device-Aided Therapy Screening in Parkinson Disease: Hubert Fernandez, MD

The director of the Center for Neurological Restoration at Cleveland Clinic discussed why gaps remain in screening for patients with Parkinson disease who may be eligible for device-aided therapies.

Atogepant’s Impact on Migraine Reductions and Patient-Reported Outcomes

Lawrence Severt, MD, PhD, discussed the results from the phase 3 ADVANCE trial of atogepant, and its effect on a number of patient-reported outcomes.

Developing Accessible Neurotechnology: Richard Gershon, PhD

The vice chair for research at the Northwestern University Feinberg School of Medicine discussed creating a mobile cognitive toolbox to be used by all populations.

Evaluating, Expanding on Responsive Neurostimulation in Older Adults: Vineet Punia, MD, MS

The neurologist from Cleveland Clinic stressed the potential for responsive neurostimulation in older populations with epilepsy and the need for expanded research.

Improving Access, Standardization of Post-Stroke Smoking Cessation Treatments

Neal Parikh, MD, discussed the inconsistencies with access to treatment regimens aimed at improving smoking cessation in post-stroke patients.

Lower Sodium Oxybate for Excessive Sleepiness, Narcolepsy, and Hypersomnia: Nancy Foldvary-Schaefer, DO, MS

The director of the sleep disorders center at Cleveland Clinic discussed the data on lower sodium oxybate presented at AAN 2021.

Regulatory Outlook for Atogepant in Migraine: Lawrence Severt, MD, PhD

The director at AbbVie discussed the timeline for when a regulatory decision may come for migraine treatment atogepant, and whether additional trials are necessary.

Pimavanserin: Hopes for FDA Approval in Dementia-Related Psychosis

Clive Ballard, MD, the executive dean at the University of Exeter Medical School, discussed the safety and efficacy profile of pimavanserin (Nuplazid; Acadia Pharmaceuticals).

Understanding Disparities in Stroke Care: Sana Somani, MD, MBBS

The vascular neurology fellow at the University of Maryland Medical Center discussed her study’s findings as well as further research she would like to conduct.

Leaving a Nebulous State of Care for Patients With NMOSD: Bruce Cree, MD, PhD

The clinical research director at the UCSF Multiple Sclerosis Center shared some of the takeaways from his research for the clinical community of specialists treating patients with NMOSD.

Better Defining Multiple Sclerosis Categorization: Daniel Ontaneda, MD, PhD

The associate professor of Neurology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University discussed the potential of a data-driven approach to classifying patients with MS.